ASTELLAS PHARMA A/S: Financial statements 2014
CVR: 10888638
Source: annual report 2014, Danish Business Authority
01/04/2013 – 31/03/2014
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2014. In 2014, the company reported revenue of EUR 97,029,000 and a net result of EUR 6,989,000 compared with EUR 5,714,000 the year before. That is an increase of 4.4% compared with the year before. The profit margin was 7.2%. Equity in the 2014 report amounted to EUR 38,437,000. The solvency ratio was 76.2%. The company had 112 employees in the financial year.
- Revenue
- EUR 97,029,000
- Gross Profit
- EUR 26,535,000
- Profit/Loss
- EUR 6,989,000
- Equity
- EUR 38,437,000
- Total Assets
- EUR 50,410,000
- Employees
- 112
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | 97 mio. EUR | 26.5 mio. EUR | 7 mio. EUR | 38.4 mio. EUR | 112 |
| 2013 | 93 mio. EUR | 23.6 mio. EUR | 5.7 mio. EUR | 34.4 mio. EUR | 90 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of October 10, 2014, EY Godkendt Revisionspartnerselskab has been appointed auditor of ASTELLAS PHARMA A/S.
As of October 10, 2014, JUT NR. 2180 A/S has stepped down as auditor of ASTELLAS PHARMA A/S.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.